<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30804" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Urea Cycle Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stone</surname>
            <given-names>William L.</given-names>
          </name>
          <aff>East Tennessee State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basit</surname>
            <given-names>Hajira</given-names>
          </name>
          <aff>Brookdale University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jaishankar</surname>
            <given-names>Gayatri B.</given-names>
          </name>
          <aff>ETSU</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>William Stone declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hajira Basit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gayatri Jaishankar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30804.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Urea cycle disorders are inborn errors of metabolism resulting from defects in one of the enzymes or transporter molecules involved in the hepatic removal of ammonia from the bloodstream. Removal of ammonia from the bloodstream normally occurs via its conversion to urea, which is then excreted by the kidneys. Consequently, urea cycle disorders lead to an accumulation of ammonia. Ammonia is extremely toxic, particularly to the central nervous system. Newborns with severe mutations in any one of the first four enzymes of the urea cycle can become catastrophically ill within 36 to 48 hours of birth despite appearing normal at birth. It is therefore possible for a newborn to be discharged from the hospital before signs of urea cycle disorders develop. The newborn may subsequently develop signs that go unrecognized at home. Hyperammonemia is key to the diagnosis of urea cycle disorders and treatment should not be delayed while a definitive diagnosis is sought. This activity reviews the evaluation and management of urea cycle disorders and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients and families.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain why the potential for urea cycle disorders poses a risk to early discharge of seemingly healthy newborns.</p></list-item><list-item><p>Explain how high serum ammonia level should be managed in a newborn.</p></list-item><list-item><p>Explain the management of urea cycle disorders.</p></list-item><list-item><p>Explain the importance of improving coordination amongst the interprofessional team to enhance care for patients affected by urea cycle disorders.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30804&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30804">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30804.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Urea cycle disorders (UCDs) are inborn errors of metabolism (IEMs) resulting from defects in any 1 of the six enzymes or 2 transporters involved in the hepatic removal of ammonia from the bloodstream by conversion to urea which is excreted by the kidneys&#x000a0;<xref ref-type="bibr" rid="article-30804.r1">[1]</xref> &#x000a0;IEMs fall into two very&#x000a0;broad categories: deficiencies in specific enzymes needed to convert fat or carbohydrate into energy, or deficiencies in specific enzymes needed to break down amino acids or other metabolites thereby&#x000a0;allowing them to accumulate and become toxic if not treated.&#x000a0; UCDs fall into the second category.&#x000a0;The turnover of proteins releases amino acids, and their deamination generates ammonia.</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; -2H</p>
        <p>+H3N-CHR-COO-&#x000a0; &#x000a0;--&#x0003e;&#x000a0; O=CR-COO-&#x000a0; +&#x000a0; NH4+</p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+H2O</p>
        <p>Ammonia is extremely&#x000a0;toxic, particularly to the central nervous system (CNS). Newborns with severe mutations in any one&#x000a0;of the first four enzymes of the urea cycle (see figure 1 and below) can become catastrophically ill within 36 to 48 hours of birth despite appearing normal at birth. It is possible, therefore, that a newborn can be discharged from the hospital before signs of UCDs develop and subsequently develop signs that go unrecognized at home. Hyperammonemia is key in diagnosing UCDs and treatment should not be delayed while trying to reach a final diagnosis.</p>
      </sec>
      <sec id="article-30804.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of UCDs is complex since multiple proteins and 2 subcellular compartments are involved, i.e., the mitochondrial matrix and cytoplasm <xref ref-type="bibr" rid="article-30804.r2">[2]</xref>. The first 2 enzymatic steps in the urea cycle take place in the mitochondrial matrix. In step 1, carbamoylphosphate synthetase I (CPS1) ligates ammonia with bicarbonate forming carbamoyl phosphate which enters the urea cycle (figure 1).&#x000a0;Stressors such as sepsis can easily initiate defects in CPS1 result in the most severe form of UCDs and hyperammonemia. It should be noted that N-acetylglutamate is an allosteric activator of CPS1. N-acetylglutamate is formed from acetyl-CoA and glutamate in a reaction catalyzed by N-acetylglutamate synthase (NAG), a mitochondrial enzyme. Defects in NAG, although very rare, mimic CPS1 UCDs and result in hyperammonemia.</p>
        <p>In step 2, the liver enzyme, ornithine transcarbamylase (OTC) catalyzes the reaction of carbamoyl phosphate with ornithine to form citrulline (figure 1). The <italic toggle="yes">OTC</italic> gene (<italic toggle="yes">SLC25A15</italic>) is located on the X chromosome, and OTC defects are inherited in an X-linked fashion. Defects in OTC are the most common cause of UCDs. OTC deficiency in males results in a severe form of UCD. In females, the severity is variable ranging from asymptomatic to severe depending upon the random nature of X chromosome inactivation. The ornithine needed for OTC must be transported into the mitochondrial matrix, and this task is accomplished by the mitochondrial ornithine translocase (ORNT1) protein. Defective ORNT1, although very rare, can result in hyperammonemia which often manifests itself later in life.</p>
        <p>Step 3 and all remaining enzymatic steps take place in the cytoplasm. In step 3, argininosuccinate synthase 1 (ASS1) catalyzes the formation of argininosuccinate from citrulline and aspartic acid.&#x000a0;Defects in ASS1 result in both citrullinemia and hyperammonemia. The second mitochondrial transporter, citrin, contributes to the cytoplasmic pool of aspartic acid by transporting aspartic out of the mitochondria and into the cytoplasm where it is needed for the urea cycle. Citrin also transports glutamate from the cytoplasm into the mitochondria. Gene <italic toggle="yes">SLC25A13</italic> codes for citrin and defects in this gene can result in both citrullinemia and hyperammonemia.</p>
        <p>Step 4 of the urea cycle (figure 1) involves the cleavage of argininosuccinate to form fumaric acid and arginine, and this reaction is catalyzed by argininosuccinate lyase (ASL). Defects in ASL can cause a severe UCD in neonates as well as an adult-onset form. In contrast to the adult-onset form in which hyperammonemia is episodic, the neonatal form results in persistent hyperammonemia if left untreated. Elevated plasma levels of both citrulline and argininosuccinate are characteristic of ASL deficiency.</p>
        <p>In the last step of the urea cycle (figure 1), the arginine from step 4 is cleaved into urea and ornithine by the arginase enzyme which is coded for by the <italic toggle="yes">ARG1</italic> gene. Defects in arginase can result in both argininemia and hyperammonemia. The signs and symptoms of arginase deficiency usually appear by 3 years of age and without a rapid onset of hyperammonemia.</p>
      </sec>
      <sec id="article-30804.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Overall, the incidence of UCDs has recently been determined to be 1 in 35,000 births. Most State Screening Laboratories currently&#x000a0;detect only 2 of all the conditions that cause UCDs. About two-thirds of all USDs are due to mutations in OTC, one-fifth due to ASS1, and one-tenth due to ASL<xref ref-type="bibr" rid="article-30804.r3">[3]</xref>.&#x000a0;</p>
      </sec>
      <sec id="article-30804.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>There has been considerable progress in understanding the pathophysiology of UCDs which may ultimately promote better medical interventions <xref ref-type="bibr" rid="article-30804.r4">[4]</xref>.&#x000a0; Hyperammonemia is a key etiological factor in UCDs and plays a key role in CNS toxicity. Although complex, some important concepts are emerging.&#x000a0; The toxic effects of ammonia on the CNS are more severe in the developing brain than in the adult brain.&#x000a0; Whether the toxic effects of hyperammonemia are reversible or not depends upon the exposure time, the dose of hyperammonemia and the stage of neurological development. In the neonatal brain, hyperammonemia results in edema caused by swelling of astrocytes. The subsequent frequency and degree of&#x000a0;swelling are key factors in determining the severity of CNS neurological disorders such as seizures, coma, and cognitive/motor deficits.</p>
        <p>While OTC deficiency (OTCD) is inherited in an X-linked manner, all other UCDs follow an autosomal recessive pattern. Moreover, there is evidence that even asymptomatic female carriers of OTCD can develop cognitive defects as a result of episodic hyperammonemia.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-30804.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Newborns with UCDs typically appear normal at birth and shortly after that can present with nonspecific signs and symptoms similar to many IEMs or an infection, i.e., lethargy, poor appetite, vomiting, and irritability. IEMs, in general, should be considered in the differential diagnosis of any infant with such signs. Except for arginase deficiency, most infants with severe UCDs rapidly develop cerebral edema, and subsequent neurological problems, resulting from acute hyperammonemia. Unless treated, hyperammonemia from severe UCDs can progress to coma and death. In cases of mild UCDs, hyperammonemia can result from a variety of stressors such as illness and surgery <xref ref-type="bibr" rid="article-30804.r4">[4]</xref>.</p>
      </sec>
      <sec id="article-30804.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A key biomarker for UCDs is hyperammonemia (&#x0003e; 150 micromolar for a neonate and &#x0003e; 100 micromolar for an infant) in the absence of high anion gap and with a normal plasma glucose level.&#x000a0; In addition to plasma ammonia, it is useful to obtain plasma amino acids and plasma lactic acid if metabolic acidosis is present.&#x000a0; The laboratory finding characteristic of UCDs include: (a) elevated levels of plasma glutamine and alanine; (b) decreased plasma arginine (except for arginase deficiency) and; (c) high or low plasma citrulline levels.</p>
      </sec>
      <sec id="article-30804.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for UCDs, or any IEM, should be done in consultation with an appropriate genetics/metabolic expert. For neonates with hyperammonemia, the immediate treatment goal is a rapid lowering of ammonia and reducing dietary protein intake. Hemodialysis is very effective at reducing plasma ammonia and should immediately be initiated if elevated hyperammonemia is observed. Ammonia scavenger medications such as Ammonul IV are also useful. Ammonul IV acts by removing glycine and glutamate from plasma thereby&#x000a0;their reducing contribution to ammonia formation.&#x000a0;</p>
        <p>N-carbamylglutamate&#x000a0;(Carbaglu) is an analog of N-acetylglutamate, and small clinical trials have found it to improve ureagenesis in NAGS deficiency and late-onset CPS1 deficiency <xref ref-type="bibr" rid="article-30804.r5">[5]</xref>.<xref ref-type="bibr" rid="article-30804.r6">[6]</xref><xref ref-type="bibr" rid="article-30804.r7">[7]</xref> More extensive clinical trials are underway.</p>
      </sec>
      <sec id="article-30804.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Anorexia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Blurring of vision</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cerebral edema</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Coma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperventilation or hypoventilation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypothermia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lethargy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Slurring of the speech</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30804.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of urea cycle disorders is complex and best done with an interprofessional team that includes a geneticist, pathologist, pediatrician, nephrologist, internist, biochemist and dialysis nurse/nurse practitioner.&#x000a0;Treatment for UCDs, or any IEM, should be done in consultation with an appropriate genetics/metabolic expert. For neonates with hyperammonemia, the immediate treatment goal is a rapid lowering of ammonia and reducing dietary protein intake. Hemodialysis is very effective at reducing plasma ammonia and should immediately be initiated if elevated hyperammonemia is observed. Ammonia scavenger medications such as an IV nitrogen binding agent are also useful. These agents act by removing glycine and glutamate from plasma thereby&#x000a0;their reducing contribution to ammonia formation.</p>
        <p>The prognosis for most of these infants is guarded.<xref ref-type="bibr" rid="article-30804.r8">[8]</xref><xref ref-type="bibr" rid="article-30804.r9">[9]</xref></p>
      </sec>
      <sec id="article-30804.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30804&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30804">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/urea-cycle-disorders/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30804">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30804/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30804">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30804.s12">
        <fig id="article-30804.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Urea Cycle Disorder Contributed by William Stone, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UCDs_organic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30804.s13">
        <title>References</title>
        <ref id="article-30804.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braissant</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in the pathogenesis of urea cycle disorders.</article-title>
            <source>Mol Genet Metab</source>
            <year>2010</year>
            <volume>100 Suppl 1</volume>
            <fpage>S3</fpage>
            <page-range>S3-S12</page-range>
            <pub-id pub-id-type="pmid">20227314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ah Mew</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Gropman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lanpher</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Summar</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <chapter-title>Urea Cycle Disorders Overview</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">20301396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Summar</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Koelker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freedenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Mons</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haberle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kirmse</surname>
                <given-names>B</given-names>
              </name>
              <collab>European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD). Electronic address: http://www.e-imd.org/en/index.phtml</collab>
              <collab>Members of the Urea Cycle Disorders Consortium (UCDC). Electronic address: http://rarediseasesnetwork.epi.usf.edu/ucdc/</collab>
            </person-group>
            <article-title>The incidence of urea cycle disorders.</article-title>
            <source>Mol Genet Metab</source>
            <year>2013</year>
            <season>Sep-Oct</season>
            <volume>110</volume>
            <issue>1-2</issue>
            <fpage>179</fpage>
            <page-range>179-80</page-range>
            <pub-id pub-id-type="pmid">23972786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waisbren</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gropman</surname>
                <given-names>AL</given-names>
              </name>
              <collab>Members of the&#x000a0;Urea Cycle Disorders Consortium (UCDC)</collab>
              <name>
                <surname>Batshaw</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-84</page-range>
            <pub-id pub-id-type="pmid">27215558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>la Marca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fiorini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Filippi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>New developments in the treatment of hyperammonemia: emerging use of carglumic acid.</article-title>
            <source>Int J Gen Med</source>
            <year>2011</year>
            <month>Jan</month>
            <day>07</day>
            <volume>4</volume>
            <fpage>21</fpage>
            <page-range>21-8</page-range>
            <pub-id pub-id-type="pmid">21403788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allegri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deplazes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rimann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Causton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scherer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leff</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Diez-Fernandez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klimovskaia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fingerhut</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krijt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ko&#x0017e;ich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nuoffer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grisch-Chan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Th&#x000f6;ny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>H&#x000e4;berle</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive characterization of ureagenesis in the spf<sup>ash</sup> mouse, a model of human ornithine transcarbamylase deficiency, reveals age-dependency of ammonia detoxification.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>1064</fpage>
            <page-range>1064-1076</page-range>
            <pub-id pub-id-type="pmid">30714172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buerger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garbade</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Dietrich Alber</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Waisbren</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>McCarter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>K&#x000f6;lker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burgard</surname>
                <given-names>P</given-names>
              </name>
              <collab>Urea Cycle Disorders Consortium</collab>
            </person-group>
            <article-title>Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain-specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>243</fpage>
            <page-range>243-253</page-range>
            <pub-id pub-id-type="pmid">30671983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Renal replacement therapy in neonates with an inborn error of metabolism.</article-title>
            <source>Korean J Pediatr</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>43</fpage>
            <page-range>43-47</page-range>
            <pub-id pub-id-type="pmid">30404428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30804.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dhawan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deheragoda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pierre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Vilca-Melendez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Had&#x0017e;i&#x00107;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Liver transplantation for neonatal-onset citrullinemia.</article-title>
            <source>Pediatr Transplant</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>e13191</fpage>
            <pub-id pub-id-type="pmid">29726081</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
